This is to inform that due to some circumstances beyond the organizer control, “International Conference on Medicinal Chemistry, Computer Aided Drug Design and Delivery” (MCADD 2023) Hybrid event during September 14-16, 2023 at Valencia, Spain has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at medicinal-chemistry@magnusconference.com or call + 1 (702) 988 2320.
A substance that binds to an enzyme and reduces its activity is known as an enzyme inhibitor. Inhibitors lower the compatibility of substrate and enzyme by attaching to their active sites, preventing the formation of Enzyme-Substrate complexes, stopping the catalysis of processes, and reducing (at times to zero) the amount of product produced by a reaction. The rate of enzyme activity reduces as the concentration of enzyme inhibitors increases, hence the amount of product generated is inversely proportional to the concentration of inhibitor molecules. Many medications are enzyme inhibitors because inhibiting an enzyme's function can kill a pathogen or rectify a metabolic imbalance. Enzyme inhibitors are chemicals that interact with enzymes in some way, either temporarily or permanently, reducing the rate of an enzyme-catalysed reaction or preventing enzymes from functioning normally. Competitive, non-competitive, and uncompetitive inhibitors are the three main categories of inhibitors. A mixed inhibition exists in addition to these inhibitor kinds. Competitive enzyme inhibitors have a structure that is similar to that of the substrate molecule and compete with it for the enzyme's active site. This keeps enzyme-substrate complexes from forming.
Title : A qsar survey on tyrosine kinase inhibitors
Atefeh Hajiagha Bozorgi, Faculty of pharmacy, Iran (Islamic Republic of)
Title : Abbott diagnostics: COVID-19 inactivation, nucleocapsid antigen automated immunoassay development, and variant testing for automated and lateral flow assays binaxnow™ and panbio™
Philip M Hemken, Abbott Laboratories, United States
Title : Synthesis, antibacterial activity of 3-amino 5-methoxyl-2-methyl quinazolin-4(3H)-one an amino-6-methoxyl-2-methyl of 4H–benzo[d] [1,3]–oxazine–4–one
Osarumwense Peter Osarodion, Ondo State University of Sciences and Technology, Nigeria
Title : Tackling mycobacterium tuberculosis resistance with tailored isatin-pyrimidine hybrids enoyl acyl carrier protein reductase (Inha)
Amgad Albohy, The British University in Egypt (BUE), Egypt
Title : Transition metal complexes/Organometallic compounfs as anticancer drugs
Prakash kinthda, Nims university,jaipur,rajasthan, India
Title : New n-ribosides and n-mannosides of rhodanine derivatives with anticancer activity on leukaemia cell line: Design, synthesis, dft and molecular modelling studies
Ahmed, Kafrelsheikh University, Egypt